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Dual stem cell therapy synergistically improves
cardiac function and vascular regeneration
following myocardial infarction
Soon-Jung Park 1,9, Ri Youn Kim2,9, Bong-Woo Park 3,4,9, Sunghun Lee 2,9, Seong Woo Choi1,
Jae-Hyun Park4, Jong Jin Choi1, Seok-Won Kim5, Jinah Jang6, Dong-Woo Cho5, Hyung-Min Chung1,
Sung-Hwan Moon1,7, Kiwon Ban 2 & Hun-Jun Park3,4,8
Since both myocardium and vasculature in the heart are excessively damaged following
myocardial infarction (MI), therapeutic strategies for treating MI hearts should concurrently
target both so as to achieve true cardiac repair. Here we demonstrate a concomitant method
that exploits the advantages of cardiomyocytes derived from human induced pluripotent
stem cells (hiPSC-CMs) and human mesenchymal stem cell-loaded patch (hMSC-PA) to
amplify cardiac repair in a rat MI model. Epicardially implanted hMSC-PA provide a com-
plimentary microenvironment which enhances vascular regeneration through prolonged
secretion of paracrine factors, but more importantly it significantly improves the retention
and engraftment of intramyocardially injected hiPSC-CMs which ultimately restore the car-
diac function. Notably, the majority of injected hiPSC-CMs display adult CMs like morphology
suggesting that the secretomic milieu of hMSC-PA constitutes pleiotropic effects in vivo. We
provide compelling evidence that this dual approach can be a promising means to enhance
cardiac repair on MI hearts.
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Myocardial infarction (MI) is a fatal disorder that inflictsa permanent loss of cardiomyocytes (CMs) and scartissue formation, resulting in irreversible damage to
cardiac function ensued by heart failure1. While cardiac regen-
eration is considered unfeasible with current medical options,
accumulating evidence in animal models as well as clinical trials
continue to demonstrate that stem cells could offer new oppor-
tunities for treating MI hearts2.
Among them, human mesenchymal stem cells (hMSCs) have
long been considered a promising candidate for cell-based ther-
apy owed to their beneficial paracrine factors such as vascular
endothelial growth factor (VEGF), fibroblast growth factor 2
(FGF2), and hepatocyte growth factor (HGF) that promote
angiogenesis, neovascularization, and cell survival3. hMSCs are
also known to secrete potent anti-fibrotic factors including matrix
metalloproteinases 2, 9, and 14, which inhibit the proliferation of
cardiac fibroblasts thereby attenuating fibrosis4.
In tandem, CMs derived from human pluripotent stem cells
(hPSC-CMs), which include both human embryonic stem cells
(hESCs) and human induced pluripotent stem cells (hiPSC), are
propitious due to their similarities with human primary CMs
apposite to expressions of cardiac-specific genes, structural pro-
teins, and ion channels as, well as spontaneous contraction5,6.
Several preclinical studies have shown that hPSC-CMs success-
fully engraft, align, and couple with host myocardium in a syn-
chronized manner to improve cardiac function6–8.
Since the heart is an organ composed of cardiac muscles and
blood vessels, both cardiac muscles and vasculatures in the heart
were excessively damaged following MI. Thus therapeutic stra-
tegies for treating MI hearts should be focused to comprehen-
sively repair all that together for achieving true cardiac repair2.
The principality behind cell-based cardiac regeneration therapy
should adhere to the same principles as well.
Hence, in this study, we develop a multipronged approach
aiming to concurrently rejuvenate both the myocardium and
vasculatures utilizing both hiPSC-CMs and hMSCs. We hypo-
thesize that while intramyocardially injected hiPSC-CMs would
restore heart function by engraftment with the host myocardium,
epicardially implanted hMSC patches (hMSC-PA) would simul-
taneously enhance vascular regeneration through consistent
secretion of angiogenic paracrine factors in MI-induced hearts.
We demonstrate that the dual approach of applying hiPSC-CMs
as well as hMSC-PA lead to a significant improvement of cardiac
function and enhancement of vessel formation post MI. Of note,
not only do the implanted hMSC-PA significantly increase the
retention of intramyocardially injected hiPSC-CMs but also
preserve injured host CMs via paracrine release of cytokines and
growth factors, resulting in functional improvement. Surprisingly,
the majority of injected hPSC-CMs neighboring hMSC-PA dis-
play the rectangular-shaped morphology of adult-like CM and
significant expression of Gja1, a major gap junction protein,
suggesting that hMSC-PA promotes CM maturation in vivo.
Furthermore, we identify that paracrine factors released from
hMSC-PA constitute the key contributors with pleiotropic effects,
including pro-angiogenesis, anti-inflammation, anti-fibrosis, and
CM maturation. These results carry significant implications for
stem cell therapy in cardiac repair, highlighting the need for
intricate and strategic designs to achieve complete restoration.
Results
Selection of optimal hMSCs and their characterization. To
select the best candidate of hMSCs in terms of secretion of para-
crine factors, we examined distinct types of hMSCs isolated from
different sources such as human turbinate, human adipose tissue,
and human bone marrow and compared the concentration of
VEGF secreted to their conditioned medium. As a result, we found
that concentration of VEGF released from hMSCs derived from
human bone marrows were substantially higher than other types
of hMSCs (Supplementary Fig. 1A). Subsequently, we characterized
hMSCs from bone marrows and found that bone marrow-derived
hMSCs exhibited evident phenotypes of hMSCs. Cultured bone
marrow-derived hMSCs displayed a homogeneous spindle-like
shape, which is a typical cell morphology of hMSCs and express
abundant expression of several specific markers for hMSCs, such as
CD73, CD105, CD90, and CD44 (Supplementary Fig. 1B).
hMSC-PA secrets paracrine factor. First, to examine the viability
of hMSCs within the hMSC-PA, we generated hMSC-PA (Sup-
plementary Fig. 2A) and performed the live/dead staining. As a
result, we verified that that the majority of hMSCs within the
hMSC-PA remained alive and less than one-tenth of cells were
dead, indicating that hMSC-PA can maintain the viability of
hMSCs. Next, to confirm whether hMSC-PA could efficiently
release paracrine factors from embedded hMSCs, we cultured the
hMSC-PA in vitro, collected supernatants, and performed VEGF
ELISA assay (Supplementary Fig. 2B). As a result, we verified that
hMSC-PA released VEGF over time. We observed that the con-
centration of VEGF released from hMSC-PA increased in a time-
dependent manner, suggesting that hMSC-PA is capable of
releasing sufficient amounts of cytokines (Supplementary
Fig. 2B).
hMSC-PA increases the expressions of multiple factors. To
explore the paracrine effects of hMSC-PA in MI hearts in vivo, we
first performed gene expression analyses with rat heart tissues
harvested 7 days after hMSC-PA implantation into MI hearts
(Fig. 1a–d). qRT-PCR results show that hMSC-PA significantly
upregulated the expression of several angiogenesis-related genes,
such as vascular endothelial growth factor A (VEGFa), insulin-
like growth factor 1 (IGF-1), fibroblast growth factor 2 (FGF2),
placental growth factor (PLGF), angiopoietin 1 (Ang1), and
angiopoietin 2 (Ang2), and cluster of differentiation 31 (CD31) in
comparison with the MI control hearts, as well as the cell-free
patch implanted group (Fig. 1e). In addition, while expression
levels of pro-inflammatory-related genes such as interferon
gamma (IFNG), interleukin 1 beta (IL-1b), and tumor necrosis
factor alpha (TNFα) were not significantly altered, the expression
levels of anti-inflammatory-related genes including transforming
growth factor beta 1 (TGFβ1) and interleukin 10 (IL10) were
significantly increased in hMSC-PA implanted hearts (Fig. 1f). Of
interest, hMSC-PA significantly downregulated the expression of
several anti-fibrosis-related gene including collagen type 1
(COL1) and collagen type 3 (COL3) and increased the expression
of tissue inhibitors of metalloproteinase 2 (TIMP-2) (Fig. 1g).
These qRT-PCR data clearly suggest that hMSCs-PA could
induce significant paracrine effects for multiple factors regarding
angiogenesis, inflammation, and fibrosis in MI hearts.
hMSC-PA is only effective in improving angiogenesis. Given
the instant increased expression of several angiogenesis-releated
genes, we sought to investigate whether hMSC-PA could improve
vascular regeneration in MI hearts. To determine the effects of
hMSC-PA, we perfused isolectin B4 (IsB4) conjugated with green
fluorescent dye into the heart tissues to visualize the vessels prior
to tissue harvest at 8 weeks. Consistent with the qRT-PCR results,
assessment of fluorescent images showed that the number of
capillaries in the infarct zones of hMSC-PA implanted hearts
were significantly higher than the untreated control group sug-
gesting hMSC-PA have significant effects on vascular regenera-
tion in MI hearts (Fig. 2a). To ensure that the illustrated
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vasculogenic were exclusively attributed by hMSC-PA, we per-
formed a TUNEL assay using rat heart tissues harvested 8 weeks
post implantation. The results revealed that the majority of
hMSCs were located within the patch and remained alive (Sup-
plementary Figs 3, 4). hMSCs were active as less than one-tenth of
the cells exhibited TUNEL signal (Supplementary Fig. 4). These
results suggest that the observed angiogenic effects were attrib-
uted by of hMSC-PA, which was viable for at least 8 weeks fol-
lowing implantation.
Next, to evaluate cardiac function and cardiac remodeling, we
performed echocardiography on a regular basis. While there was
a substantial increase of capillary density in hMSC-PA implanted
MI hearts, the echocardiography results demonstrated that
hMSC-PA did not induce functional improvement in MI hearts.
Both ejection fraction (hMSC-PA: 33.93% ± 1.66% vs. 32.21% ±
0.67% in control group, n= 7 animals; p < 0.05; one-way
ANOVA was used for statistical analyses) and fractional short-
ening (hMSC-PA: 14.07% ± 0.81% vs. 11.56% ± 0.94% in control
group, n= 7 animals; p < 0.05; one-way ANOVA was used for
statistical analyses.) were not significantly different with the
untreated control group (Fig. 2b). Based on these results, we
postulated that although implantation of hMSC-PA is very
effective for vascular regeneration, it is insufficient to improve
cardiac function and requires additional cell sources to further
enhance heart function.
Generation of cardiomyocyte derived from hiPSCs. Owing to
several previous studies reporting the promising effects for
restoring cardiac function in MI hearts, we sought to test hiPSC-
CMs as an additional cell type to treat MI hearts. Accordingly, we
generated hiPSC-CMs by using a small-molecule-based 2D dif-
ferentiation method (Supplementary Fig. 5)9–11. Spontaneous
beating was observed around differentiation day 7 (Supplemen-
tary Fig. 5B and Supplementary Movies 1, 2). Immunostaining
demonstrated that most differentiated hiPSC-CMs displayed CM-
specific marker proteins, such as TNNT2 and ACTN2 (Supple-
mentary Fig. 5C). Furthermore, quantification analyses per-
formed via flow-cytometry analysis demonstrated an upwards of
98% of hiPSC-CMs were positive for TNNT2, and ~84% of
hPSC-CMs expressed MYL2, a well-known marker for ventricular
CMs suggesting successful generation of highly purified hiPSC-
CMs (Supplementary Fig. 5D).
Dual approach increases cardiac function and angiogenesis.
Subsequently, we investigated the therapeutic potential of the
dual approach by intramyocardially injecting hPSC-CMs and
implanting hMSC-PA (Supplementary Movie 3). After the
induction of MI by LAD ligation, we generated five experimental
groups receiving: (i) Sham control, (ii) untreated control, (iii)
hiPSC-CM intramyocardial injections, (iv) hMSC-PA implanta-
tions, or (v) both hiPSC-CMs and hMSC-PA, and compared their
therapeutic effects. First, echocardiography results showed that
cardiac function in the combined treatment group was sig-
nificantly higher than hiPSC-CM only or hMSC-PA-only
group, as determined by ejection fraction (hiPSC-CMs (CM):
35.95% ± 1.85% vs. combined (CM+ PA): 43.15% ± 0.52% vs.
hMSCs hdECM
hMSC-patch
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Fig. 1 Implantation of hMSC-PA into MI hearts enhances the expression of multiple factors. a Preparation of heart-derived decellularized extracellular
matrix (hdECM) bioink. b Macroscopic view and illustration of 3D printing system used to produce PCL platform. c Schematic illustration of human
mesenchymal stem cell patch (hMSC-PA). Scale bar: 4 cm. d Epicardially implanted hMSC-PA in MI heart at 1 week. e-g Quantitative real-time polymerase
chain reaction analysis of relative mRNA expression of multiple factors in the myocardium at 1 week after hMSC-PA implantation in MI induced hearts.
e angiogenesis (f) inflammation, (g) fibrosis. The y-axis represents relative mRNA expression of target genes to GAPDH. A.U. indicates arbitrary units. The
data are represented as mean ± SEM. +p < 0.05 compared with MI group, #p < 0.05 compared with PA-only group; n= 3 biologically independent samples
per group. One-way ANOVA was used for statistical analyses. Control: MI control, PA-only: cell-free hdECM patch, and hMSC-PA: hMSC-loaded patch
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32.21% ± 0.67% in the control group, n= 7 animals; p < 0.05;
one-way ANOVA was used for statistical analyses.) and fractional
shortening (hiPSC-CM (CM): 15.02% ± 0.85% vs. hiPSC-CMs+
hMSC-PA (CM+ PA): 18.61% ± 0.26% vs. 11.56% ± 0.94% in the
control group, n= 7 animals; p < 0.05; one-way ANOVA was
used for statistical analyses.) (Fig. 3a). Finally, the therapeutic
effects of our complementary approach was directly compared
with a dual injection group (Dual-IN), which received an intra-
myocardial injection of a cell mixture (hiPSC-CMs, hMSCs,
and hdECM). An echocardiography taken at 2, 4, and 8 weeks
showed that both EF and FS of the CM+ PA group was sig-
nificantly higher than the Dual-IN group at both 4 and 8 weeks
(Supplementary Fig. 6).
Moreover, histological images demonstrated that the number
of capillaries (mm2) in the both border zone and infarct zone of
the hearts from the complementary group were substantially
higher than the control and the hiPSC-CMs only group (Fig. 3b).
The number of functional capillaries (diameter range: 5–10 μm)
in the complementary group was significantly higher than other
test groups (Supplementary Fig. 7). Importantly, the combined
treatment group significantly decreased cardiac fibrosis. The
results from Masson’s trichrome staining using cardiac tissue
harvested at 8 weeks exhibited an area of fibrosis (%) was
significantly lower in combined treatment groups compared with
other experimental groups (Fig. 3c; Supplementary Fig. 8 and
Supplementary Movies 4, 5). Collectively, these results clearly
indicate that the combined treatment lead to comprehensive
cardiac repair through the improvement of cardiac function, as
well as vascular regeneration and reduction of cardiac fibrosis.
hMSC-PA enhance the engraftment of hiPSC-CMs. Interest-
ingly, we found that implantation of hMSC-PA significantly
improved the retention of intramyocardially injected hiPSC-CMs.
The injected hiPSC-CMs were tracked in heart tissues by using
two distinct types of hiPSC-CMs: (1) hiPSC-CMs continuously
expressing the green fluorescence signal (hiPSC-CMs-GFP)
(Supplementary Fig. 9 and Supplementary Movies 6, 2) hiPSC-
CMs pre-labeled with a potent red florescence dye, CM-DiI, prior
to cell injection (Supplementary Fig. 10). Immunostaining with
human-specific antibodies for the MYH7 protein and mito-
chondria further verified the identity of hiPSC-CM-GFP as
human CMs (Fig. 4a, b). Next, the number of hiPSC-CMs that
remained in heart tissues was quantified at different time points
by harvesting the samples obtained from two different experi-
mental groups (CM vs. CM+ PA) at 2, 4, and 8 weeks after
administration. Cell counting was conducted manually, and there
was significant difference in the number of hiPSC-CMs between
the two groups. The CM+ PA group displayed a substantially
higher count than that of the CM group (Fig. 4c). Notably, the
CM+ PA group also showed hiPSC-CMs distributed throughout
all regions of the left ventricle while the CM group showed
hiPSC-CMs only localizing near the injection sites (Supplemen-
tary Fig. 10). Both groups were able to retain the majority of
hiPSC-CMs within the infarct zone and the cells remained viable
until 8 weeks following injection as evidenced by the TUNEL
assay (Fig. 4d).
hMSC-PA improves the maturity of hiPSC-CMs. Remarkably,
immunohistochemistry with TNNT2 and MYH6/7 antibodies
revealed that the CM+ PA group evidently displayed a more
mature form (Fig. 4e; Supplementary Fig. 11). While the mor-
phology of hiPSC-CMs in the CM group exhibited a typically
immature globular phenotype, the CM+ PA group exhibited a
much larger rod-shaped structure that resembled adult-like CMs.
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These effects were also reflect in vitro when 10 or 30% of hMSC-
conditioned media (hMSC-CA) collected from hMSC culture
greatly increased the size of cultured neonatal rat ventricular
cardiomyocytes (NRVM). The expression level of genes related to
CM maturation was not altered in any significant way in excep-
tion to cardiac troponin T (TNNT2). Collectively, these results
indicate the proteomic milieu secreted by hMSCs are a dominant
factor in CM maturation (Supplementary Fig. 12).
More importantly, concomitant staining with Gja1, a major gap
junction protein, further showed that a substantial number of
engrafted hiPSC-CMs in the CM+ PA group formed gap junctions
with host CMs (Fig. 4f; Supplementary Fig. 13). Limited expression
of Gja1 in the CM group suggests the supportive and essential role
of hMSC-PA in the formation of gap junctions between the injected
hiPSC-CMs and host CMs (Fig. 4f; Supplementary Fig. 13). In
addition, the results from multi-electrode arrays (MEAs) using co-
cultured hiPSC-CMs and NRVM in vitro exhibited a well-
synchronized action potential, suggesting a well-coupled syncytium
between two CMs. No visible sign of arrhythmogenic beating was
detected during the recording period (Supplementary Fig. 14 and
Supplementary Movie 7). Taken together, these results suggest that
hMSC-PA can markedly enhance cell retention, improve functional
maturation, and induce integration with the host myocardium in
MI hearts.
Cytokines secreted from hMSCs increases angiogenesis. To
identify detailed therapeutic mechanism of hMSC-PA, we per-
formed various types of in vitro analyses. Among the first, to test
whether hMSCs directly promote angiogenesis, we conducted cell
migration and tube-formation assays using conditioned media
(CM) collected from cultured hMSCs (hMSC-CM). At first, we
performed the scratch assay, an in vitro experiment for measuring
endothelial cell (ECs) proliferation/migration, which are critical
steps of angiogenesis. As shown in Fig. 5a, the addition of 10% of
hMSC-CM significantly enhanced the migration of HUVEC and
induced faster closure of the cell-free gap compared with the
control group, suggesting that cytokines secreted by hMSCs
enhanced the mobility of ECs (Fig. 5a). Next, the results from
Matrigel tube-formation assay, which was carried out to evaluate
vessel-forming capability, showed that tube length and branches
assessed 9 h later were significantly higher in the 10% hMSC-CM-
treated HUVEC compared with untreated control HUVEC
(Fig. 5b).
The effects of hMSCs for EC proliferation were further
examined by our co-culture system with hMSCs and HUVEC.
As shown in Fig. 5c, the proliferation rate of HUVEC was
significantly higher than HUVEC monoculture control group
when they were co-cultured with hMSCs (Fig. 5c). On the first
day, both the monoculture and co-culture plates expanded at
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roughly the same rate (×105), but a clear difference in growth rate
appeared on day 2. The size of HUVEC droplet and cell number
in the co-culture plate was markedly higher than those in
monoculture of HUVEC, indicating that the factors secreted from
hMSCs have significant vasculogenic potential by proliferation
and migration of ECs. Collectively, these results indicated that
enhanced vessel formation shown in a number of in vitro assays
was due to the angiogenic factors secreted from hMSCs, which is
consistent with our in vivo results.
hMSC-secreted factors improve the survival of hiPSC-CMs.
Given the ability of hMSC-PA to improve the survival and
retention of injected hiPSC-CMs, we sought to examine
whether hMSC-CMs exerted direct cytoprotective effects in
hiPSC-CMs in vitro. Ischemic injury was simulated by exposing
hiPSC-CMs to H2O2. Administration of hMSC-CMs sig-
nificantly improved cell viability as determined by the
Annexin V assay and lactate dehydrogenase (LDH) release. As
shown in Fig. 6, treatment with 10% of hMSC-CM substantially
decreased the number of both PI and Annexin-positive cells
(Fig. 6a). Furthermore, the results from LDH assays revealed
that LDH released from hMSC-CM-treated hiPSC-CMs was
significantly lower than untreated control hiPSC-CMs, sug-
gesting hMSC-CM possess cardioprotective effects against
ischemic insults (Fig. 6b). We also observed that cytokines
released by hMSCs were able to induce CM migration in a
chemotactic manner as hiPSC-CMs began to migrate towards
hMSCs after 12 h and reached the center of the dish at 72 h.
Within 48 h, hiPSC-CMs (black arrow) continued to approach
the periphery of hMSCs which is indicative of cell–cell affinity
(Supplementary Fig. 15).
Cytokine array in BM-MSC conditioned medium. Lastly, to
identify the panel of factors secreted by hMSCs, we prepared the
hMSC-CM from hMSC cultures at two different time points at
day 7 and 14 and analyzed them via Proteome Profiler Human
Arrays (Fig. 7)12,13. The following families of cytokines were
observed from hMSC-CM; angiogenesis (angiopoietin 1, vasorin,
progranulin, IGFBP-2, IGFBP-7, VEGF, DKK-1, DKK-3, IL-6, IL-
8, uPA), ECM remodeling (MMP-1, MMP-13, MMP-20,
thrombospondin-1, TIMP-1, TIMP-2, TIMP-3, latent TGF-beta,
bp1), cell viability (EDA-A2, GDF-15, IL-1 sRII, MCP-1, MIP-2),
and inflammation (IL-28A, lymphotactin, activin A, GRO)
(Fig. 7).
Discussion
In this study, we demonstrate a approach in treating MI that
exploits the providential advantages of both hiPSC-CMs and
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hMSC-PA to significantly amplify cardiac repair. Synergistic
effects of intramyocardially injected hiPSC-CMs and epicardially
implanted hMSC-PA collectively rejuvenated the myocardium
and vessels post MI. Epicardially implanted hMSC-PA provided a
complimentary microenvironment which enhanced vascular
regeneration through prolonged secretion of beneficial paracrine
factors as expected, but more importantly it improved the
retention, distribution, engraftment, and maturation of hiPSC-
CMs which ultimately augmented heart function and restored the
injured myocardium (Fig. 8).
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Indeed, there have been several previous studies that describe
the beneficial effects of hPSC-CMs5–8 or hMSCs14–16 or other cell
types, such as cardiac progenitor cells17,18, endothelial cells19–21,
and smooth muscle cells20,21, on MI either separately or as a
combinatory20–22. These individual type of cells or cell mixtures
were delivered to the hearts through direct intramyocardial
injection5–8 or as a patch form19,21,23 formulated by using several
different types of biomaterials. Compared with those previous
reports, this study is, to the best of our knowledge, the first to
simultaneously examine the effects of two distinct major stem cell
types delivered via two different routes for inducing compre-
hensive cardiac repair.
A primary obstacle to cell-based cardiac therapy is the extre-
mely low rate of retention and engraftment to the host myo-
cardium which is particularly important because degree of cell-
based cardiac repair largely depends on the number of cells that
survive and engraft within the heart24–26. In this regard, our
histological results revealed a substantial increase in the retention
and thereby engraftment of intramyocardially injected hiPSC-
CMs when paired with epicardial hMSC-PA. The absence of
hMSC-PA resulted in a rapid decline of the hiPSC-CM
population over time to dwindling levels by 8 weeks, whereas its
presence greatly bolstered the number of survivals for subsequent
engraftment (Fig. 4c). From this, we presumed that the paracrine
factors secreted by hMSC-PA improved the survival and
engraftment of hiPSC-CMs by enabling the cells to more resistant
to the hostile microenvironment in ischemic tissues, particularly
during the early stage of implantation, which is critical for cell
engraftment and survival. We also envisioned that the placement
hMSC-PA over the epicardium may have also served as a bio-
physical barrier preventing the mechanical expulsion of injected
hiPSC-CMs into the epicardial space, further contributing to the
increased retention rate of hiPSC-CMs.
Notably, we found that hMSC-PA promoted the maturation of
injected hiPSC-CMs in MI hearts. Our histological analyses
results demonstrated that hiPSC-CMs together with hMSC-PA
led to a more elongated and rectangular cell shape, which are
typical morphological characteristics of matured adult CMs.
Those hiPSC-CMs stained more strongly for CM-specific MYH6/
7 and TNNT2, and exhibited striations with Z-bands running
longitudinally along the hiPSC-CMs. They were also more
compact and better oriented with adherent intercalated discs.
More importantly, they showed significant expression of gap
junctions, GJA1, which allows for more efficient electrical and
mechanical integration of the host myocardium (Supplementary
Fig. 14). In contrast, hiPSC-CMs injected without hMSC-PA
showed an immature morphology and expressed minimal levels
of GJA1. Thus, it seemed to be that the secreted factors released
from hMSC-PA provided the cues necessary for enhancing CM
maturation (Supplementary Fig. 12). There is increasing recog-
nition that hPSC-CMs represent immature CMs at an embryonic
or fetal stage and are functionally and structurally different from
mature CMs27. It has been shown that hPSC-CMs at day 30 post
differentiation are still small and have disarrayed myofibrils28.
Hence, these underdeveloped characteristics of hPSC-CMs may
significantly limit their usage for further applications. Performing
additional studies to identify a secreted factor(s) from hMSCs that
can promote the maturation of hPSC-CMs are highly required.
Even though this study evidenced several promising results,
there are some limitations to the study that require consideration.
Since our complementary approach (CM+ PA) was examined in
a permanent ischemia model, the outcomes may be different if
applied to models with advanced heart failure. In addition, the
majority of cardiac imaging results was solely obtained by
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echocardiography in this study. Future studies employing more
advanced cardiac imaging methods such as Magnetic resonance
imaging (MRI) and PET imaging will warrant more accurate and
sophisticated cardiac analyses. Lastly, this approach necessitates
somewhat complicated technical and surgical procedures to
successfully inject hiPSC-CMs and implant hMSC-PA to the
heart. Follow-up studies should be carried out to develop a more
concise surgical method that can take full advantage of this
approach with less invasive procedures.
In summary, we report a strategy for cardiac repair which can
concurrently rejuvenate both the myocardium and vasculatures
through two major types of stem cells.
Epicardial patch carrying hMSCs improved vascular regen-
eration and promoted engraftment and viability of the injected
hiPSC-CMs leading to subsequent restoration of cardiac function.
Our study highlights the unique advantages of different cell types,
and their appropriate use can significantly advance cell-based
cardiac therapy.
Methods
Mesenchymal stem cells derived from human bone marrow. Human
mesenchymal stem cells derived from the bone marrow (hMSCs; Catholic MAS-
TER Cells) were obtained from Catholic Institute of Cell Therapy (CIC, Seoul,
Korea). Human bone marrow aspirates were obtained from the iliac crest of
healthy donors aged 20 to 55 years after approval by the Institutional Review Board
of Seoul St. Mary’s Hospital (approval numbers KIRB-00344–009 and KIRB-
00362–006). We have complied with all relevant ethical regulations for work with
human participants and obtained informed consent. Bone marrow aspirated from
each consented donor was collected and sent to the GMP-compliant facility of
Catholic Institute of Cell Therapy (Seoul, Korea, http://www.cic.re.kr) for the
isolation, expansion, and quality control of hMSCs. The marrow mixture was
centrifuged at 4 °C, 793 g for 7 min to obtain a marrow pellet. After removal of the
supernatant, red blood cells were removed by adding and suspending in tenfold
volume of sterile distilled water. Cell pellet obtained by centrifugating the RBC-
deprived sample, was then suspended in the MSC growth medium (Dulbecco’s
modified Eagle’s medium-low glucose (DMEM-LG, PAA), 10% fetal bovine serum
(FBS, Gibco). They were added to 100 -mm tissue culture dish (TTC), which was
placed in a CO2 incubator to initiate culture. The incubator was maintained at
37 °C with 5% CO2. The MSC growth medium was used for all cell expansion
procedures, unless mentioned otherwise. Media were replaced twice per week. Cells
were detached when they reached 70–90% confluence and replated at a density of
5–8 × 103 cells/cm2. Cells were expanded 2 to 4 passage in the GMP-compliant
facility. During cell expansion, cells were tested for bacterial sterility, mycoplasma
sterility, and endotoxin level (<3 EU/mL). In addition, multi-differentiation
potential and cellular surface antigens (CD90/CD73, >95% positive; CD34/CD45,
>95% negative) were tested for cells after 4th passage.
Manufacturing hMSC-PA using hdECM. The heart-derived decellularized
extracellular matrix (hdECM) isolated from porcine heart tissues was prepared by
following methods that we originally reported29. The heart tissue from a 6-month-
old Korean domestic pig was purchased from a local livestock product market in
Korea29 and we dissected the left ventricle to cut into small pieces. Then the small
pieces of heart tissues were soaked in a 1% sodium dodecyl sulfate (Affimetrix, CA)
solution for 48 h followed by treatment with 1% triton X-100 solution in PBS
(Biosesang, Korea) for 1 h. Next, the decellularized tissues were dipped in the PBS
for 3 days to remove the residual detergent. Subsequently, the decellularized heart
tissues were lyophilized, pulverized in liquid nitrogen, and digested in 10 mL of
0.5 M acetic acid solution (Merck Millipore, Billerica, MA) at a final concentration
of 3.3 w/v% (330 mg of hdECM powder) supplemented with 33 mg of pepsin
powder. The digested hdECM solution was filtered through a 40 -µm pore mesh,
aliquoted in 1 ml, and stored at −20 °C for further experiments. Before manu-
facturing the hMSC-PA, the hdECM solution was adjusted to a neutral pH of 7.4
by adding 10 N NaOH solution, while keeping the conical tube in an ice bucket to
avoid gelation of hdECM.
To generate hMSC-PA, we first produced a disk-shaped polycaprolactone (PCL)
with 8 -mm diameter and 0.5- mm height as a supporting framework by using a 3D
printer according to the generated code (Fig. 1b). Then, we built up the bioink by
mixing the hMSCs (1 × 106/ml), hdECM (20mg/ml), and 0.02% (w/v) of vitamin B2
and applied the bioink on the PCL framework generated by 3D printing (Fig. 1c).
Subsequently, hMSCs-PA was exposed to UVA light for about 60 s to initiate a
vitamin B2-induced post-cross-linking process (light intensity: 30 mW/cm2) and
kept them at 37 °C for 24 h for additional thermal cross-linking. After all these
procedures, final thickness and diameters of hMSC-PA were averaged 3mm and
8mm, respectively.
Generation of cardiomyocytes from hiPSCs. hiPSCs (DF19–9–11T)30,31 cell line
was purchased from WiCell® and maintained on Matrigel using the mTeSR1
(STEMCELL Technologies) medium after approval from the Institutional Review
Board of Seoul St. Mary’s Hospital (approval number KIRB-0050210–007). Sub-
sequently, to initiate the differentiation into cardiac lineage, hiPSCs were then
seeded onto a hPSC qualified Matrigel (Corning)-coated cell culture dish
(Eppendorf) at 140,000 cells/cm2 dish. 5 μM Y-27632 (Tocris) was added for the
first 24 h after pasage. The medium was changed daily, and hiPSCs were allowed to
grow in mTeSR1 for 3–4 days until the cells were 90% confluent. At day 0,
cells were treated with CHIR99021 (Tocris) 8 μM/ml in CDM (cardiomyocyte
differentiation medium: RPMI1640 (ThermoFisher Scientific)/BSA (Sigma-
Aldrich)/ascrobic acid (Sigma-Aldrich). After 48 h, the medium was changed to
CDM supplemented with 3 μM/ ml C59 (Wnt inhibitor/Stemgent Inc.) for another
48 h9–11. At day 5, the medium was replaced with CDM and freshly changed every
2 days. Spontaneously, contracting cells began to appear at ~day 6 to day 10. From
day 10 to day 15, the medium was replaced with CDM containing L-lactic acid to
metabolically select and purify cardiomyocytes (hiPSC-CMs)32. All live images
were taken with a Lumasope 720 microscope (Etaluma).
Generation of hiPSC-CM-GFP. hiPSCs expressing GFP signal (hiPSC-GFP) was
generated by using pMXs-EGFP retroviral vector. Briefly, the pMXs-EGFP retro-
viral vector was purchased from Addgene and transfected into the 293FT cells
using the chemical method, Lipofectamine 2000 (Invitrogen). After 48 h, the virus-
containing supernatants were collected, filtered through a 0.45-μm Milex-HV filter
(Millipore), and then concentrated using Retroconcentin (SBI; Mountain View,
CA). Subsequently, these were transfected to 5.0 × 105 of hiPSC (DF19–9–11T) in
opti-MEM media (Life Technologies) supplemented with 4 mg/mL polybrene
(Millipore). Finally, hiPSC colonies expressing GFP signal were FACS sorted based
on the expression of EGFP at 3–4 days post retroviral transduction (Supplementary
Fig. 9). The purified fraction of hIPSC-GFP colonies were expanded for further
differentiation into the CMs. Finally, hiPSC-GFP were differentiated into the
hiPSC-CMs-GFP through the previously used CM differentiation protocol.
Myocardial infarction model and cell/patch delivery. All animal studies were
approved by Animal Care and Use Committee in the Catholic University of Korea.
We have complied with all relevant ethical regulations for animal testing and
research. Fischer 344 rats (180–200 g, male, Orientbio, Korea) were anesthetized
with 2% inhaled isoflurane and intubated via the trachea with an 18-gauge intra-
venous catheter. The rats were then mechanically ventilated with medical grade
oxygen. Animals were placed on a 37 °C heating pad to prevent cooling during
procedure. After shaving the chest, a left thoracotomy was performed. MI was
achieved by tying a suture with sterile polyethylene glycol tubing (22 G) placed into
the left anterior descending (LAD) artery for 1 min, and then the knot was per-
manently ligated using a 7–0 prolene suture. To establish baseline left ventricular
function, the ejection fraction (EF) and regional wall motion abnormalities
(RWMA) were examined post operation day (POD) 7 (inclusion criterion: EF
<45% by echocardiographic evaluation). On the same day, rats were anesthetized
again using isoflurane inhalation, intubated and mechanically ventilated. The
animal chest was re-opened, and the pericardium was partially removed from the
infarcted heart. Then, hiPSC-CMs (1.0 × 106 per rat) were injected at two different
sites in the border zone of infarcted myocardium and the hMSC-PA was implanted
directly on the epicardium using two sutures (Supplementary Movie 3). To trace
the injected hiPSC-CMs within the heart tissues, we used CM-DiI (Chlor-
omethlybenzamido, CellTracker TM). The stock solution was prepared using a
modification of the manufacturer’s instructions. From a 1mg/ml CM-DiI stock
solution in DMSO, 5 μM solutions were made in 500 μl of the DMEM and this
working solution was used to label the hiPSC-CMs. The chest was closed asepti-
cally, and antibiotics and 0.9% normal saline solution was given. All rats received
following immunosuppressants (azathioprine, 2 mg/kg; cyclosporine A, 5 mg/kg;
methylprednisolone, 5 mg/kg) daily.
Echocardiography. The assessment of functional improvement for injured cardiac
tissues was performed with echocardiography26,33,34. The rats were lightly anes-
thetized with inhaled isoflurane, and physiological data were recorded by using
Transthoracic echocardiography system equipped with a 15MHz L15–7io linear
transducer (Affniti 50 G, Philips). Serial echocardiograms were performed at 2, 4,
and 8 weeks after treatment. The echocardiography operator was blinded to the
group allocation during the experiment. Ejection fraction (EF) and fractional
shortening (FS), which are indexes of LV systolic function, were calculated with the
following equations, respectively:
EF %ð Þ ¼ LVEFDD3  LVESD3 =LVEDD3   100 ð1Þ
FS %ð Þ ¼ LVEDD LVESDð Þ=LVEDD½   100 ð2Þ
Flow-cytometry analysis. hMSCs were re-suspended in 100 μl of FACS solution
(1% FBS in PBS) then incubated with PE-conjugated mouse anti-human 1:250
CD90 (BD Biosciences # 555596), 1:250 CD73 (BD Biosciences # 550257), 1:250
CD105 (BD Biosciences # 560839), and APC-conjugated mouse anti-human 1:250
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CD44 (R&D System, FAB4948A). In case of hiPSC-CMs, hiPSC-CMs were first
washed twice with PBS for 1 min at RT followed by 0.05% Trypsin-EDTA (ther-
mos) for 3–4 min at 37 °C. After re-suspension and fixation with PFA/permeabi-
lized solution (BD Bioscience) for 15 min and stained using 1:700 TNNT2 (Cardiac
troponin T; Thermo Fisher #MA5–12960) and ACTN2 (α-sarcomeric actinin;
Sigma-aldrich #A7811) IgG antibodies for 12 h at 4 °C. Secondary staining was
performed with antibody 1:1000 Alexa Fluor 488 goat anti-rabbit IgG (Thermo
Fisher #A11008) and 1:1000 Alexa Fluor 555 goat anti-mouse IgG (Thermo Fisher
#A21422) antibodies for 1 h at RT. All cells were analyzed using a FACSCalibur,
Cell Quest software (BD Biosciences) with the exception of hiPSC-GFP which was
sorted through a SH800S Cell Sorter flow cytometer with Cell sorter software Ver
2.1.2 (Sony Biotechnology).
Quantitative real-time RT-PCR. The total RNAs were extracted by the addition of
0.5 mL of TRIzol reagent (Life Technologies) to cells on a plate as described in the
manufacturer’s instructions. One microgram of RNA was subjected to cDNA
synthesis with SuperScriptTM Reverse Transcriptase IV and random primers
(Invitrogen). SYBR® Green PCR Master Mix (Applied Biosystems) was used to
detect the accumulation of PCR product during cycling with the ABI Real-time
PCR StepOne Plus (Applied Biosystems). Real-time reverse transcription-
polymerase chain reaction (RT-PCR) was carried out in triplicate in at least three
independent experiments. Oligonucleotide primers were designed using real-time
RT-PCR system sequence detection software v2.3 (Applied Biosystems), and their
sequences are provided in Supplementary Table 1. Fold differences in the
expression level of each gene were calculated for each treatment group using CT
values normalized to transcript levels of the housekeeping gene, 18S rRNA or
GAPDH, according to the manufacturer’s instructions.
Capillary density measurement. At the time of sacrifice, hearts were perfused
with GFP-conjugated Isolectin B4 from Griffonia simplicifolia (Vector Lab) for
15 min at room temperature. Hearts were then fixed in 4% paraformaldehyde
overnight before embedding in OCT compound (Thermo Scientific) with dry ice.
In all, 10- µm cross-sections of the heart were made by using HM525 NX Cryostat
(Thermo Scientific) starting from the apex to top. The sections were stored in
−80 oC before use. The number of capillaries were counted in five random
microscopic fields using a fluorescence microscope (Nikon) and expressed as the
number of capillaries per square millimeter tissue.
Determination of fibrosis. Masson’s Trichrome (MT) staining (Sigma) was per-
formed to determine the fibrosis area of MI hearts. Briefly, three frozen sections
were fixed in Bouin’s solution at 56 °C for 15 min in each group. These sections
were stained using Weigert’s iron hematoxylin solution for 5 min at room tem-
perature and also stained using Biebrich Scarlet-acid Fuchsin solution for 2 min at
room temperature. Finally, the sections were counterstained with Aniline Blue for
5 min, followed by incubation in 1% acetic acid for 2 min at room temperature.
Extensive washes were performed between each step. The collagen fibers appeared
blue and viable myocardium appeared red. The percent of the area of fibrosis to
entire left ventricular wall area was quantified using ImageJ software with basic
add-ons.
Immunocytochemistry. Cells were plated onto gelatin-coated glass dish and cul-
tured for 5 days. Then cells were fixed with 4% PFA for 20 min at 4 °C, permea-
bilized with 0.1% BSA in 0.03% Triton X-100 for 10 min at room temperature
(RT), and blocked in 10% normal goat serum (NGS, ThermoFisher Scientific) in
0.03% Triton X-100 for 30 min at RT. Subsequently, the cells were stained with
1:100 CD90 (Abcam #Ab225), 1:500 TNNT2 (Thermo Fisher #MA5–12960), and
1:200 ACTN4 (Sigma-aldrich #A7811) overnight at 4 °C in 0.03% Triton X-100.
Cell were washed three times for 10 min, with 0.03% Triton X-100 and incubated
for 1 h at RT in the dark with secondary antibody 1:1000 Alexa Fluor 488 goat anti-
rabbit IgG (ThermoFisher Scientific) and Alexa Fluor 555 goat anti-mouse IgG
(ThermoFisher Scientific) on a shaker. Cells were washed four times before nuclei
were stained with DAPI (Thermo Fisher). All images were analyzed using a
fluorescence microscope, Nikon TE2000-U (Nikon, Japan).
Immunohistochemistry. Immunofluorescence was performed on 10-µm-thick
sections. Following permeabilization with PBS containing 0.5% Triton X-100 for
15 min and blocking with 1% BSA in PBS for 60 min at room temperature, the
sections were incubated with primary antibodies diluted in PBS containing 1% BSA
and 1% Tween 20 at 4 °C overnight. Primary antibodies used in this study include
1:100 CD90 (Abcam #Ab225), 1:100 MYH6/7 (Abcam #Ab50967), 1:100 TNNT2
(Thermo Fisher #MA5–12960), 1:200 ACTN4 (Sigma-Aldrich #A7811), 1:100
GJA1 (Abcam #Ab11370), 1:100 human MYH7 (Abcam #Ab172967), and 1:100
human mitochondria (Abcam #Ab92824). After washing three times with 1%
Tween 20 in PBS, the samples were incubated with secondary antibodies for 60 min
at room temperature in the dark. Secondary antibodies used in this study include
either 1:400 anti-mouse IgG Alexa Fluor 488 (Invitrogen #A10680) or 1:400 anti-
rabbit IgG Alexa Fluor 647 (Invitrogen #A21245). After washing again with 1%
Tween 20 in PBS, the sections were stained with DAPI solution (VectaShield) for
nuclear staining and then mounted on slides. Imaging of heart sections was
performed with a Laser Scanning Microscope LSM 880 NLO with Airyscan pro-
cessing (Zeiss).
Multi-electrode array measurements. In vitro co-cultures of NRVM and hiPSC-
CM were prepared. NRVMs and hiPSC-CMs were mixed at a ratio of 8 to 2 and
seeded to a multi-electrode array (MEA) chamber (60MEA200, Multi Channel
Systems, Reutlingen, Germany). Electrophysiological recording was performed
7 days after seeding. During the measurement, CM was placed in the MEA
recording apparatus (MEA2100-System, Multi Channel Systems) maintained at
37 °C and 5% CO2. Spontaneous electrical activity of CM was recorded for 20 min.
The recording and analysis of conduction velocity was performed and calculated
with Cardio2D program (Multi Channel Systems).
TUNEL assay. TUNEL staining was performed via an In situ Apoptosis Detection
kit (Invitrogen), as the manufacturer instructed. After TUNEL staining, heart
sections were stained with antibodies specific for CMs or hMSCs. Samples were
imaged under a confocal microscope, and five views were randomly selected from
each section to quantify the number of TUNEL-positive cells.
Production of hMSC-conditioned medium. hMSCs (2 × 106) were seeded onto
100 -mm dishes, and were cultured until 80–90 % confluency. Cells were then
washed with PBS, and the medium was changed to low glucose DMEM (Lonza)
without FBS. After 7 of 14 days of culture, the supernatants were collected and kept
at 4 °C for further experiments.
Tube-formation assay. Basement membrane matrix (Matrigel®, BD Biosciences)
was added to two-well chamber slides and solidified by incubation at 37 °C for
30 min. Overall, 1 × 105 human umbilical vein endothelial cells (HUVECs) were
plated onto each Matrigel-containing well with DMEM/F12 medium containing
20% KnockOut serum replacement, 1% nonessential amino acids, 0.1 mM β-mer-
captoethanol, 4 ng/mL of FGF2, 10 ng/ml VEGFA, 10 ng/ml EGF, and 25 ng/ml
DLL4 and incubated at 37 °C for 12 h. After removing the media, 4% PFA was
added for fixation. The tube structures were evaluated by microscopy.
Endothelial cell-migration assay. HUVEC (3.5 × 104 cells/well) were cultured in a
well separated by a Culture-Insert 24 (ibidi, Martinsried, Germany). Next, to record
the migration of cells to the cell-free gap, the culture inserts were removed after
24 h and cultured in EBM-2 media (Lonza) supplemented with 10% hMSC-
conditioned media for another 18 h35. Subsequently, the migration area was digi-
tally photographed during the indicated hours (0, 6, 12, and 18 h) and area of the
cell-free gap was calculated by using ImageJ software (version 6.0, NIH). Migration
rate was determined and expressed as a percentage of closure relative to the initial
size at 0 h36. All images were taken with a Lumasope 720 microscope (Etaluma) in
time-lapse at 5 min intervals.
Endothelial cell proliferation assay. A co-culture system involving hMSCs and
HUVECs (Lonza) was used to evaluate the proliferation of HUVECs. The pro-
liferation rate of HUVEC droplets (1 × 104 cells; 10 μl) co-cultured with BM-MSCs
were measured12. Briefly, a total of 2 × 105 hMSCs were seeded in the upper layer
of 35 -mm plates and cultured with 2% FBS in the DMEM medium. After 4 h,
HUVEC droplets (1 × 104 cells; 10 μl) were carefully placed into the bottom layer of
each well. The HUVEC droplets were allowed to adhere at 37 °C for 3 h followed by
the addition of medium. Subsequently, H&E staining was carried out to measure
the size of HUVEC droplet. Lastly, the total number of HUVECs per plate was
quantified. Both HUVEC droplet size and cell number were quantified for 3
consecutive days.
Cytoprotective effects of hMSCs conditioned medium. To investigate whether
hMSCs conditioned medium could provide cytoprotective effects against ischemic
insult, 10% hMSC-conditioned medium was added into hiPSC-CM culture con-
taining hydrogen peroxide (H2O2) (200 μM), simulating conditions of myocardial
ischemia in vitro. Following 2 h exposure to H2O2, both hiPSC-CMs and
culture medium were harvested. First, hiPSC-CMs were examined by using
Annexin V–FITC kit (Biolegend) to measure the apoptosis, and the results were
analyzed by SONY® flow cytometer (SH800, Sony Biotechnology, Inc., Tokyo
Japan) with sony software 2.1.2version. In addition, lactase dehydrogenase (LDH)
assay (LDH cytotoxicity assay kit, Sigma) was performed by using culture medium
to measure cellular damage. Briefly, 50 μL of culture medium was collected from
various groups of hiPSC-CM cultures (in triplicate) and transferred into a 96-well
plate. After adding an equivalent volume of LDH reagent into each well, the
absorbance was measured using a spectrophotometer at a wavelength of 492 nm
with a reference wavelength of 620 nm. For more accurate measurements, the
absorbance of the no-cell controls was subtracted from the readings of hiPSC-CM
samples.
Cardiomyocyte migration assay. hiPSC-CMs and hMSCs were cultured on
Culture-Insert 2 well (ibidi) at 2 × 104 cells/well. The culture inserts were removed
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11091-2
10 NATURE COMMUNICATIONS |         (2019) 10:3123 | https://doi.org/10.1038/s41467-019-11091-2 | www.nature.com/naturecommunications
after 36 h. Both cell types were cultured in the RPMI medium supplemented with
2% FBS for 48 h at 37 °C. The migration area was digitally photographed at the
indicated hours (0, 12, 24, and 48 h). All images were taken with a Lumasope 720
microscope (Etaluma) in time-lapse videos at 3 min intervals.
Cytokine array. hMSC-conditioned medium was analyzed by using biotin label-
based human antibody array I membrane for 507 human proteins (RayBiotech,
Norcross, GA)13,37.
Statistical analysis. All quantitative data are shown as means ± SE unless other-
wise indicated. The statistical differences between two groups were analyzed by
two-tailed Student’s t tests. The Statistical differences among three or more groups
were analyzed by one-way ANOVA with Bonferroni’s post hoc analysis. The results
were considered statistically significant when the p-value was less than 0.05.
Data availability
The data that support the findings of this study are available from the corresponding
authors upon reasonable request.
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